Arcus Biosciences, Inc.RCUSEarnings & Financial Report
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
Revenue
$8.0M
Gross Profit
N/A
Operating Profit
$-122.0M
Net Profit
$-112.0M
Gross Margin
N/A
Operating Margin
-1525.0%
Net Margin
-1400.0%
YoY Growth
-20.0%
EPS
$-1.14
Arcus Biosciences, Inc. Q1 FY2025 Financial Summary
Arcus Biosciences, Inc. reported revenue of $8.0M (down 20.0% YoY) for Q1 FY2025, with a net profit of $-112.0M (down 2700.0% YoY) (-1400.0% margin).
Key Financial Metrics
| Total Revenue | $8.0M |
|---|---|
| Net Profit | $-112.0M |
| Gross Margin | N/A |
| Operating Margin | -1525.0% |
| Report Period | Q1 FY2025 |
Arcus Biosciences, Inc. Annual Revenue by Year
Arcus Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $33.0M).
| Year | Annual Revenue |
|---|---|
| 2025 | $33.0M |
| 2024 | $51.0M |
| 2023 | $37.0M |
| 2022 | $38.0M |
Arcus Biosciences, Inc. Quarterly Revenue & Net Profit History
Arcus Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $11.0M | -52.2% | $-106.0M | -963.6% |
| Q3 FY2025 | $6.0M | -14.3% | $-135.0M | -2250.0% |
| Q2 FY2025 | $8.0M | -27.3% | $0 | N/A |
| Q1 FY2025 | $8.0M | -20.0% | $-112.0M | -1400.0% |
| Q4 FY2024 | $23.0M | +146.9% | $-94.0M | -408.7% |
| Q3 FY2024 | $7.0M | -78.1% | $-92.0M | -1314.3% |
| Q2 FY2024 | $11.0M | -62.1% | $-93.0M | -845.5% |
| Q1 FY2024 | $10.0M | -60.0% | $-4.0M | -40.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $11.0M | $7.0M | $23.0M | $8.0M | $8.0M | $6.0M | $11.0M |
| YoY Growth | -60.0% | -62.1% | -78.1% | 146.9% | -20.0% | -27.3% | -14.3% | -52.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.29B | $1.19B | $1.25B | $1.15B | $1.16B | $1.07B | $974.0M | $1.14B |
| Liabilities | $586.0M | $551.0M | $687.0M | $665.0M | $625.0M | $526.0M | $538.0M | $508.0M |
| Equity | $707.0M | $635.0M | $565.0M | $485.0M | $531.0M | $549.0M | $436.0M | $631.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.0M | $-94.0M | $26.0M | $-100.0M | $-132.0M | $-133.0M | $-97.0M | $-120.0M |